Bayer Aktiengesellschaft (LON:0P6S)
London · Delayed Price · Currency is GBP · Price in EUR | Market Cap | 40.89B +71.9% |
| Revenue (ttm) | 39.07B -1.7% |
| Net Income | -1.50B |
| EPS | -1.52 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 10.44 |
| Dividend | 0.10 (0.23%) |
| Ex-Dividend Date | Apr 27, 2026 |
| Volume | 702,807 |
| Open | 48.37 |
| Previous Close | 48.41 |
| Day's Range | 47.45 - 48.50 |
| 52-Week Range | 25.79 - 54.00 |
| Beta | 0.83 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 4, 2026 |
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and ge... [Read more]
Financial Performance
In 2025, Bayer Aktiengesellschaft's revenue was 45.58 billion, a decrease of -2.21% compared to the previous year's 46.61 billion. Losses were -3.62 billion, 41.8% more than in 2024.
Financial numbers in EUR Financial StatementsNews
Bayer to present data from cardiovascular, kidney, stroke programs at ESC 2026
Bayer (BAYRY) today announced that 11 oral presentations across its cardiovascular, kidney, and secondary stroke prevention programs will be featured at the European Society of Cardiology, ESC, Congre...
Bayer to Present New Phase III Data from Its Cardiovascular, Kidney, and Stroke Clinical Trial Programs at ESC 2026
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer today announced that 11 oral presentations across its cardiovascular, kidney, and secondary stroke prevention programs will be featured at the Euro...
Bayer price target raised to EUR 61 from EUR 50 at JPMorgan
JPMorgan raised the firm’s price target on Bayer (BAYRY) to EUR 61 from EUR 50 and keeps an Overweight rating on the shares.
Bayer Aktiengesellschaft Earnings Call Transcript: Q2 2026
Sales grew 3% to EUR 24.3 billion in H1 2026, with strong performance in Crop Science and new pharma products offsetting declines in mature brands. Litigation risks eased after a favorable U.S. Supreme Court ruling, and capital structure was strengthened by Apollo's equity investment and new bond issuance.
Bayer Aktiengesellschaft Quarterly report: Q2 2026
Bayer Aktiengesellschaft has published its Q2 2026 quarterly earnings report on August 4, 2026.
Bayer Aktiengesellschaft Slides: Q2 2026
Bayer Aktiengesellschaft has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
Bayer Aktiengesellschaft Earnings release: Q2 2026
Bayer Aktiengesellschaft released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Bayer Aktiengesellschaft Slides: Corporate presentation
Bayer Aktiengesellschaft has posted slides in relation to its latest quarterly earnings report, which was published on August 4, 2026.
Bayer raises FY26 sales view to EUR 44.7B-EUR 46.7B from EUR 44.5B-EUR 46.5B
The company said, “Bayer (BAYRY) has affirmed its currency-adjusted Group guidance for full-year 2026 for all metrics except net financial debt, which it now expects to come in lower than…
Bayer says ‘advancing’ on strategic priorities
Bayer (BAYRY) is also advancing its other strategic priorities, CEO Bill Anderson said, pointing to progress in rejuvenating the Pharmaceuticals pipeline and executing the Five-Year Framework to impro...
Bayer Aktiengesellschaft Earnings Call Transcript: Q2 2026
Sales grew 3% to EUR 24.3 billion in H1 2026, with margin gains in Crop Science and resilience in Pharma. Litigation risk eased after a favorable Supreme Court ruling, and capital structure was strengthened by a EUR 3 billion Apollo investment and $5 billion bond issue.
Bayer Aktiengesellschaft Quarterly report: Q2 2026
Bayer Aktiengesellschaft has published its Q2 2026 quarterly earnings report on August 4, 2026.
Bayer Aktiengesellschaft Earnings release: Q2 2026
Bayer Aktiengesellschaft released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Bayer Swings to Net Profit on Smaller Litigation Charges
The company said its 2026 sales and earnings forecasts were unchanged when adjusted for currency changes, and that year-end net debt would be lower than originally projected.
Drugmakers, retailers must face 'maximum strength' claim in decongestant false ad litigation in US
A federal appeals court on Thursday revived portions of nationwide litigation in which consumers accused drugmakers such as Procter & Gamble and retailers such as CVS of selling billions of dollars o...
New Economist Enterprise Research Highlights Why Integrating Self-Care Into Health Systems Matters
LEVERKUSEN, Germany--(BUSINESS WIRE)--Self-care, when effectively integrated into health systems, can improve health outcomes, expand access to healthcare services and reduce pressure on overstretched...
Kairos Pharma announces collaboration with Bayer to enhance XOFIGO
Kairos Pharma (KAPA) announced a strategic collaboration with Bayer (BAYRY) to evaluate Kairos Pharma’s lead antibody ENV-105, a first-in-class CD105/BMP signaling inhibitor, in combination with Bayer...
Bayer, Henry Ford Health partner to expand access to clinical trials
Bayer (BAYRY) and Henry Ford Health announced a strategic partnership to expand clinical trial opportunities for patients. The work brings together Bayer’s global drug development expertise with Henry...
Bayer and Henry Ford Health Announce Strategic Research Partnership to Expand Patient Access to Clinical Trials
DETROIT--(BUSINESS WIRE)--Bayer, a global life sciences company, and Henry Ford Health today announced a strategic partnership to expand clinical trial opportunities for patients. The work brings toge...
Sabanto announces oversubscribed Series B funding led by Leaps by Bayer
Sabanto announced an oversubscribed Series B funding led by Leaps by Bayer (BAYRY) with participation by Sustainable Forward Capital, InnoVenture Iowa, Fulcrum Global Capital, DCVC, and Yara. The roun...
Pesticide makers stack wins against US environmental, public health groups
The U.S. Supreme Court handed a major legal victory to German agrichemical and pharmaceutical company Bayer last month when it reined in thousands of lawsuits accusing the German company of failing to...
Bayer secures EUR 3B to improve capital structure
Bayer (BAYRY) has secured EUR 3B in equity capital to improve its capital structure. The company signed a respective agreement with the global asset management firm Apollo (APO) on Friday.
Apollo to Buy $3.4 Billion Stake in Bayer Contraceptives Business
The asset-management firm agreed to buy a minority stake in Bayer's long-acting reversible contraceptives business.
Bayer gets €3 billion in Apollo deal for contraceptives unit
Bayer said on Friday it had secured €3 billion ($3.4 billion) in equity from Apollo-managed funds in a deal tied to its long-acting reversible contraceptives, or LARC, business, aiming to bolster i...
Bayer enters alliace with University of Colorado Anschutz, UCHealth
Bayer (BAYRY) announced a new strategic alliance focused on clinical trials collaboration with the University of Colorado Anschutz, UCHealth and Children’s Hospital Colorado, establishing Bayer’s firs...